Raymond James & Associates Boosts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Raymond James & Associates boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 206,713 shares of the company’s stock after purchasing an additional 4,885 shares during the quarter. Raymond James & Associates’ holdings in Teva Pharmaceutical Industries were worth $2,158,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in Teva Pharmaceutical Industries by 5.5% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 19,315 shares of the company’s stock worth $176,000 after purchasing an additional 1,000 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Teva Pharmaceutical Industries by 2.7% in the fourth quarter. Marshall Wace LLP now owns 48,771 shares of the company’s stock valued at $445,000 after acquiring an additional 1,273 shares in the last quarter. ClariVest Asset Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 0.4% in the third quarter. ClariVest Asset Management LLC now owns 399,900 shares of the company’s stock valued at $4,079,000 after acquiring an additional 1,400 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Teva Pharmaceutical Industries by 0.8% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 178,827 shares of the company’s stock valued at $1,824,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Teva Pharmaceutical Industries by 1.7% in the fourth quarter. Nordea Investment Management AB now owns 89,136 shares of the company’s stock valued at $931,000 after acquiring an additional 1,521 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 390,738 shares of company stock worth $5,132,766. 0.62% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $13.10 on Wednesday. The firm has a market capitalization of $14.69 billion, a PE ratio of -27.87, a P/E/G ratio of 1.54 and a beta of 1.05. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The business has a 50-day moving average of $13.43 and a two-hundred day moving average of $11.19. Teva Pharmaceutical Industries Limited has a 12 month low of $7.09 and a 12 month high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. As a group, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several recent research reports. The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a research report on Friday, March 8th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.